Overview

Comparative Bioavailability Study of Synerx and Verelan PM 300 mg Verapamil HCl ER Capsules Under Fed Conditions

Status:
Completed
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the bioequivalency of Synerx Pharma Verapamil extended release capsules.
Phase:
Phase 1
Details
Lead Sponsor:
Synerx Pharma, LLC
Treatments:
Verapamil